Patient‐derived mouse xenografts from pediatric liver cancer predict tumor recurrence and advise clinical management

Delphine Nicolle, Monique Fabre, Marina Simon‐Coma, Aurore Gorse, Roland Kappler, Lara Nonell, Mar Mallo, Hazar Haidar, Olivier Déas, Charlotte Mussini, Catherine Guettier, Marie‐José Redon, Laurence Brugières, Maria Rosa Ghigna, Elie Fadel, Louise Galmiche‐Rolland, Christophe Chardot, Jean‐Gabriel Judde, Carolina Armengol, Sophie Branchereau, Stefano Cairo – 26 April 2016 – Identification of new treatments for relapsing pediatric cancer is an unmet clinical need and a societal challenge.

Combined liver–dual kidney transplant: Role in expanded donors

Marco Di Laudo, Matteo Ravaioli, Gaetano La Manna, Giorgia Comai, Matteo Cescon, Massimo Del Gaudio, Chiara Zanfi, Alessandro Cucchetti, Giorgio Ercolani, Antonio Daniele Pinna – 26 April 2016 – Kidney injury is a common clinical feature among liver transplantation (LT) candidates that heavily affects prognosis and complicates the surgical decision‐making process. Up to 20% of patients undergoing LT demonstrate some degree of renal impairment, and 2% will benefit from a combined liver‐kidney transplantation (LKT).

Hepatitis B e antigen and its precursors promote the progress of hepatocellular carcinoma by interacting with NUMB and decreasing p53 activity

Dan Liu, Lei Cui, Yuan Wang, Guifang Yang, Jing He, Ruidong Hao, Chengpeng Fan, Mengmeng Qu, Zhepeng Liu, Min Wang, Lang Chen, Hui Li, Deyin Guo – 22 April 2016 – Hepatitis B viral infection is one of the leading causes of hepatocellular carcinoma (HCC) worldwide. Although several viral factors have been identified that may increase the risk for HCC development, the molecular mechanisms leading to the transformation of normal hepatocytes into cancer cells remain elusive.

Subscribe to